康恩貝(600572.SH):部分董監高及核心管理人員合計增持65.5萬股
格隆匯11月30日丨康恩貝(600572.SH)公佈,公司於近日收到公司部分董事、監事、高級管理人員及核心管理人員增持公司股份的通知,基於對公司未來持續穩定發展的堅定信心及對康恩貝投資價值的判斷和認可,同時為了穩定和提升市場投資者信心,公司部分董監高及核心員工於2021年11月29日和11月30日以自有(自籌)資金通過上海證券交易所集中競價交易系統增持公司股份合計65.5萬股(佔公司在中國證券登記結算有限責任公司上海分公司辦理回購股份註銷後總股本的0.0255%。公司註銷回購股份減少註冊資本的工商變更手續尚在辦理),增持均價4.16元/股,增持金額合計272.48萬元.
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.